US Election 2016
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
CDER Director's' video advises focusing on the work and "keeping our heads down."
Latest From US Election 2016 &BioPharmaceutical
When it comes to drug pricing, one size certainly doesn’t fit all. Biopharma firms need to devise and design appropriate pricing and commercial strategies for payers, a group of customers that don’t all care about the same things and, in some cases, whose needs may be diametrically opposed.
Having sat on the sidelines during the unsuccessful effort to repeal and replace Obamacare, the pharma industry may find the rest of its legislative agenda, from taxes to even user fee reauthorization, could become more difficult.
Pfizer CEO Ian Read explains why industry has stayed on the sidelines during the current health reform debate and defends drug pricing practices during a speech to the National Press Club.
President's pledge to merge drug pricing control with a revamp of the Affordable Care Act wins applause at Kentucky rally, where the president reeled through a number of his populist issues, even as the idea makes scant legislative progress.
Elias Zerhouni says Sanofi's ongoing R&D revamp has produced improved innovative results with controlled spending, in part by emphasizing cutting-edge product development ahead of research.
Allergan, Pfizer, Bristol-Myers Squibb, AbbVie, GSK, Sanofi and Roche showed glimpses in recent earnings calls of potential impacts on their global manufacturing networks from a US plan to legislate border-adjusted tax cuts. But there was not a word about President Trump’s threat of tariffs.
Less than a month after his inauguration, President Donald Trump has both unnerved and empowered industry sectors with his immediate actions or divulged potential reforms. Execs offered measured reaction and some speculation during recent earnings calls.
Former US FDA Commissioner Mark McClellan suggests the key with agency regulations may be how they are interpreted, and providing predictability and clarity, rather than just the scope of what’s written.
Novartis CEO Jimenez suggests Trump Administration may help remove regulatory barriers to US outcome-based contracting between manufacturers and payers; Duke Margolis Center for Health Policy plans policy initiative to promote value-based purchasing for drugs, medical devices and gene therapy.
You must sign in to use this functionality.
Please Sign In
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with active subscriptions will be able to access the full article. All other readers will be directed to the abstract and may purchase the article.